Latest Commercialisation News

EMVision Medical Devices has activated five of six pivotal trial sites for its emu™ bedside brain scanner, advancing towards FDA clearance while launching a parallel innovation study in Australia.

Ark Mines has awarded a contract for a 2,500m drilling campaign at its Sandy Mitchell project, aiming to significantly expand its rare earth mineral resource ahead of a key feasibility study.

Wide Open Agriculture Limited reminds shareholders of the imminent closing of its Securities Purchase Plan, offering shares at a discounted price with free options, while gearing up for an investor webinar to discuss company progress.

Kinetiko Energy has signed a non-binding term sheet with FFS Refiners to co-develop a pilot LNG plant at Brakfontein, aiming to fast-track gas production and supply to South Africa's industrial market.

Critica Limited has appointed Jacob Deysel as CEO to accelerate development of its Jupiter Rare Earth Project, signalling a strategic shift from exploration to production readiness. Deysel’s extensive global mining experience and rare earths expertise position the company for its next growth phase.

Prescient Therapeutics has launched a $7 million Share Purchase Plan at a notable discount to fund the next phase of clinical trials for its promising PTX-100 cancer therapy. The capital raise aims to accelerate progress toward regulatory approval and patient access.

Artrya Limited announces a strategic leadership reshuffle with co-founder John Konstantopoulos stepping into the CEO role as the company prepares for its U.S. commercial launch of the Salix® AI-powered platform.

Orthocell Limited has posted a record quarterly revenue of A$2.73 million, driven by strong Australian sales of its nerve repair product Remplir™, with US market expansion poised to accelerate in FY26.

Energy World Corporation Ltd plans to convert $440.5 million of debt into shares at a significant premium, reshaping its capital structure and boosting major shareholders’ stakes. Concurrently, the company announces key leadership changes to steer its next growth phase.

First Graphene Limited has secured two significant orders totaling approximately A$165,000 for its PureGRAPH graphene products, signaling growing market acceptance and supporting its FY25-26 sales outlook.

Rhythm Biosciences has obtained a $1 million non-dilutive loan backed by its FY2025 R&D Tax Incentive rebate, aiming to accelerate the commercial rollout of its ColoSTAT® test and expand its geneType™ platform.

ClearVue Technologies has secured $746,574 through a mix of equity and debt to support its international commercialisation efforts amid shifting market conditions.